Henan Newland Pharmaceutical Co. Ltd. A Market Cap ($515.21 Million)
Market Cap & Net Worth: Henan Newland Pharmaceutical Co. Ltd. A (301277)
Henan Newland Pharmaceutical Co. Ltd. A market cap. Henan Newland Pharmaceutical Co. Ltd. A (SHE:301277) has a market capitalization of $515.21 Million (CN¥3.52 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #11775 globally and #3330 in its home market, demonstrating a -2.60% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Henan Newland Pharmaceutical Co. Ltd. A's stock price CN¥8.98 by its total outstanding shares 392078400 (392.08 Million). Also see 301277 cash flow conversion for how efficiently the company converts equity into cash flow.
Henan Newland Pharmaceutical Co. Ltd. A Market Cap History (2022–2026)
Henan Newland Pharmaceutical Co. Ltd. A market cap history from 2022 to 2026. Data shows change from $745.75 Million to $515.21 Million (-15.97% CAGR). Check today's stock price for Henan Newland Pharmaceutical Co. Ltd. A for real-time trading data and today's change.
Henan Newland Pharmaceutical Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Henan Newland Pharmaceutical Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 301277 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.01x
Henan Newland Pharmaceutical Co. Ltd. A's market cap is 1.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.58x
Henan Newland Pharmaceutical Co. Ltd. A's market cap is 5.58 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $745.75 Million | $627.36 Million | $132.30 Million | 1.19x | 5.64x |
| 2023 | $832.07 Million | $651.44 Million | $158.98 Million | 1.28x | 5.23x |
| 2024 | $793.47 Million | $726.44 Million | $173.63 Million | 1.09x | 4.57x |
| 2025 | $676.43 Million | $672.38 Million | $121.25 Million | 1.01x | 5.58x |
Competitor Companies of 301277 by Market Capitalization
Companies near Henan Newland Pharmaceutical Co. Ltd. A in the global market cap rankings as of November 5, 2026. Also see total assets of Henan Newland Pharmaceutical Co. Ltd. A for a full breakdown of the balance sheet.
Key companies related to Henan Newland Pharmaceutical Co. Ltd. A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Henan Newland Pharmaceutical Co. Ltd. A (2022–2026)
Market capitalization of Henan Newland Pharmaceutical Co. Ltd. A from 2022 to today. Between 2022 and today, Henan Newland Pharmaceutical Co. Ltd. A's market cap moved from $745.75 Million to $ 515.21 Million, with a yearly change of -15.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥515.21 Million | -23.83% |
| 2025 | CN¥676.43 Million | -14.75% |
| 2024 | CN¥793.47 Million | -4.64% |
| 2023 | CN¥832.07 Million | +11.58% |
| 2022 | CN¥745.75 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Henan Newland Pharmaceutical Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $515.21 Million USD |
| MoneyControl | $515.21 Million USD |
| MarketWatch | $515.21 Million USD |
| marketcap.company | $515.21 Million USD |
| Reuters | $515.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Henan Newland Pharmaceutical Co. Ltd. A
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naph… Read more